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Background
The effects of chimerism on outcomes following allogeneic hematopoietic stem cell trans-
plantation (HSCT) are unclear and may differ between diseases. We retrospectively eval-
uated the association between chimerism and transplant outcomes in children with non-
malignant diseases.
Methods
Chimerism was evaluated using short-tandem repeat polymerase chain reaction 
(STR-PCR) in 48 patients, with mixed chimerism (MC) defined as greater than 1% recipient 
cells.
Results
The only variable exerting a significant influence on patients’ chimerism status was the 
number of infused CD34＋  cells. MC was detected in 23 transplants (9 showing transient 
MC; 10 with sustained low levels [≤30%] of autologous cells; and 4 with high-level MC 
[＞30%]). The degree of STR-PCR at 28 days after HSCT was significantly higher in patients 
with high-level MC than those with transient or low-level MC. All patients with transient 
or low-level MC successfully maintained engraftment and showed a clinical response to 
HSCT, whereas 2 of the 4 patients with high-level MC experienced graft failure. The in-
cidences of grades II-IV acute and chronic graft-versus-host disease (GVHD) were sig-
nificantly higher in patients with complete donor chimerism (CC) than MC. We observed 
no significant survival differences between CC and MC groups. However, the survival 
rate was lower in patients with high MC than those with low-level or transient MC 
(P=0.03). 
Conclusion
In non-malignant diseases, MC may indicate a tolerant state with a decreased incidence 
of GVHD. However, high-level MC may signify an increased risk of graft failure and a lower 
survival rate.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation 
(Allo-HSCT) is a well-established treatment for several non- 
malignant diseases, including severe aplastic anemia (SAA), 
inherited bone marrow failure (BMF) syndromes, im-
munodeficiencies, and metabolic disorders [1]. Although 
complete donor hematopoiesis is a desirable outcome of al-
lo-HSCT in malignant disorders, complete replacement of 
the recipient’s hematopoietic system is not considered neces-
sary to improve the underlying disease state in patients with 
non-malignant disorders. This coexistence of host and donor 
hematopoietic cells is known as mixed chimerism (MC).
Rates of graft failure and rejection are high in patients 
with non-malignant diseases [2, 3]. MC has been linked 
to graft rejection [4, 5], suggesting that early testing for 
posttransplant chimerism may help to identify patients at 
increased risk of graft rejection, who may therefore require 
immunotherapy [6]. Although patients with a significant Korean J Hematol 2011;46:258-64.
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Table 1. Characteristics of patients and donors.
N
Patients
Follow-up duration, months, median (range)
Male/Female
Median age, years, median (range)
No. CD34×10
6/kg infused, median (range)
Diseases
Bone marrow failure (BMF)
Severe aplastic anemia
Fanconi anemia
Other diseases in BMF
a)
Hemophagocytic lymphohistiocytosis
Chronic granulomatous disease
Wiskott–Aldrich syndrome
Severe combined immunodeficiency
Neurodegenerative diseases
b)
Donors
Matched related (8/8)
Mismatched related
1 mismatch (7/8)
2 mismatches (6/8)
≥3 mismatches (≤5/8)
Matched unrelated (8/8)
Mismatched unrelated
1 mismatch (7/8)
2 mismatches (6/8)
≥3 mismatches (≤5/8)
Stem cell source
Bone marrow
Peripheral blood
Cord blood
Conditioning regimen
BMF
Myeloablative
Reduced
Non-BMF
Myeloablative
Reduced
T-cell depletion
Yes
No
48
41 (8-138)
36/12
8.4 (0.6-20.5)
8.38 (1.0-32.9)
37
27
4
6
5
1
1
1
3
11
2
1
8
15
 
7
3
1
17
27
4
8
29
7
4
9
39
a)Other diseases in BMF: 2 pure red cell anemia, 2 congenital 
amegakaryocytic thrombocytopenia, 1 Kostmann disease, and 1 
congenital dyserythropoietic anemia. 
b)Neurodegenerative disea-
ses: 2 Krabbe disease and 1 adrenoleukodystrophy.
proportion of host cells are known to be at increased risk 
of rejection in cases of malignant disease, only a few studies 
have focused exclusively on children with non-malignant 
diseases [7, 8]. Furthermore, the utility of chimerism in pre-
dicting subsequent transplant outcomes in non-malignant 
diseases has not yet been established.
The main aims of this study were to identify the variables 
affecting chimerism and to determine the impact of MC 
on transplantation outcomes in patients undergoing al-
lo-HSCT for non-malignant diseases.
MATERIALS AND METHODS
1. Patients and donors
Between April 2000 and March 2011, 48 children under-
went 50 allo-HSCTs for non-malignant diseases at the Asan 
Medical Center Children’s Hospital in Seoul, Korea. In this 
study, we analyzed the initial HSCT data from all patients. 
Median age at first HSCT was 8.4 years (range, 0.6-20.5 
years), and the median duration of follow-up was 41 months 
(range, 8-138 months). Diseases were classified as BMF or 
non-BMF. All donor-recipient pairs were fully typed for 
HLA-A, -B, -C, and -DR using high-resolution molecular 
typing. As a surrogate marker of iron overload at the time 
of transplantation, serum ferritin was routinely measured 
as a part of the pretransplant work-up before the beginning 
of the conditioning regimen using a 2-site sandwich immuno-
assay with direct chemiluminescence (ADVIA Centaur, 
Siemens). All patients were stable, without fever or other 
events, suggesting that pretransplant ferritin levels are a good 
estimator of iron status and are not significantly affected 
by an inflammatory state. Data were analyzed in October 
2011. The demographic and clinical characteristics of patients 
and donors are summarized in Table 1. This retrospective 
study was approved by the institutional review board at 
the Asan Medical Center in Seoul, Korea.
2. Graft-versus-host disease
Acute and chronic graft-versus-host diseases (GVHD) 
were graded according to the established criteria [9].
3. Analysis of chimerism
Whole blood samples were collected from individual do-
nors and recipients at 1 (day 28), 2, 3, 6, and 12 months 
after allo-HSCT. In cases where MC was detected, chimerism 
was tested at more frequent intervals. DNA was prepared 
from whole blood samples using the QIAamp Blood Kit 
(Qiagen, Hilden, Germany) and quantified spectrophoto-
metrically. Polymorphic short-tandem repeat (STR) markers 
were amplified using the AmpFlSTR Profiled Plus PCR am-
plification kit (Applied Biosystems, Foster City, CA, USA). 
Amplified fragments were analyzed using an ABI PRISM 
310 Genetic Analyzer (Applied Biosystems), and peak areas 
were quantified using Genescan software (Applied Biosys-
tems). The percentages of donor and recipient DNA were 
calculated from individual proportions of donor and recipient 
peak areas [10]. Unless otherwise stated, the degrees of 
STR-PCR and MC were based on host portions.
4. Definition of chimerism and responses
Patients were stratified individually based on serial 
STR-PCR analyses, with chimerism defined as described pre-
viously [7, 8]. Patients with samples showing 1% or less 
autologous signals after HSCT were classified as having ach-
ieved complete donor chimerism (CC). We selected a cutoff 
of 1%, since microsatellite and several tandem repeat meth-
ods have a sensitivity limit of 1-5%. MC was defined as 
having a recipient fraction of 1% to 99% at any time after 
HSCT. Patients initially classified as having MC who turned 
into CC were classified in the transient MC group, while 
those showing sustained autologous signals greater than 1% Korean J Hematol 2011;46:258-64.
260 Meerim Park, et al. 
Fig. 1. Chimeric status of patients with high-level mixed chimerism.
were categorized in the sustained MC group. In the sustained 
MC group, patients consistently displaying autologous signals 
that did not exceed 30% were considered to have low-level 
MC, while those displaying a significant increase in autolo-
gous cells, up to 30%, were considered to have high-level 
MC. Patients with more than 99% recipient signals were 
defined as having attained complete recipient chimerism 
(RC) or autologous reconstitution.
Since there is no clear consensus on the definition of 
clinical remission in patients with non-malignant diseases, 
we assessed the response relative to correction of the under-
lying disease using disease-specific measures. These included 
normal hemograms along with transfusion independence in 
patients with BMF syndromes, immune reconstitution and 
lack of infection in patients with immunodeficiencies, en-
zyme concentrations and the results of brain imaging and 
neurologic examinations in patients with metabolic dis-
orders, and absence of symptoms and discontinuation of 
pretransplant-specific therapies in patients with autoimmune 
disorders [11]. A complete response (CR) was defined as 
a normal hemogram with eradication of the underlying 
disease. A partial response (PR) was defined as the presence 
of some positive effects of HSCT, but not fulfillment of the 
criteria for CR (e.g., patients with BMF that displayed some 
improvement, but were still transfusion dependent). Disease 
progression was defined as the absence of positive effects 
of HSCT.
Graft failure comprises 2 clinical entities: (1) failure to 
achieve an absolute neutrophil count of 0.5×10
9/L or less 
and marrow hypoplasia for less than 60 days with or without 
the existence of donor-type hematopoiesis, and (2) complete 
loss of donor-type hematopoiesis occurring anytime after 
transplantation. Late graft failure was defined as the loss 
of the graft after engraftment during follow-up.
5. Statistics
The probabilities of overall survival (OS) and event-free 
survival (EFS) were estimated using the Kaplan-Meier 
method. An event was defined as graft failure or death either 
due to treatment toxicity or disease progression. Fisher’s 
exact test was used to compare differences in categorical 
variables affecting chimerism and response to HSCT between 
groups, whereas the Mann-Whitney U-test was used to com-
pare continuous variables. We also attempted to model rela-
tionships between 2 continuous variables by linear 
regression. For multivariate analysis, the logistic regression 
model was used. Rreceiver operating characteristic (ROC) 
plot analysis was performed to determine the threshold value 
of CD34＋ cells for predicting chimerism. Probabilities of 
acute and chronic GVHD were calculated using the cumu-
lative-incidence-function method; death without GVHD was 
the competing event. All statistical analyses were performed 
using the SPSS statistical program (SPSS Inc., Chicago, IL, 
USA) or R 2.10.1 software (The R Foundation for Statistical 
Computing, 2007). All P-values were 2-sided, with P＜0.05 
considered statistically significant.
RESULTS
Forty-eight patients underwent allo-HSCT, and 2 required 
a second transplant due to graft failure after the first HSCT. 
At a median follow-up of 41 months, the 3-year OS and 
EFS rates were 91.5±4.1% and 85.3±5.1%, respectively. Four 
patients died, 1 due to graft failure and the other 3 due 
to transplant-related complications, including veno-occlu-
sive disease, hemorrhage, multi-organ failure, and infection.
1. Chimerism
During follow-up, 23 patients (48%) showed sustained 
CC and 23 (48%) showed MC. Peak MC in the groups of 
patients with transient (N=9), low-level (N=10), and high- 
level (N=4) MC occurred at a median of 3, 3.5, and 2.3 
months, respectively. Patients with transient MC achieved 
CC at a median of 7.7 months after HSCT. All 4 patients 
with high-level MC showed more than 30% autologous sig-
nals within 2 months after HSCT. The chimeric status of 
patients with high-level MC is shown in Fig. 1.
Two of the 4 patients with high-level MC subsequently 
experienced graft failure after HSCT (Table 2). One of these 
patients (UPN 88) achieved CR after the second HSCT, but 
died due to transplant-related complications resulting in mul-
tiple organ failure after 5 months. The second patient (UPN 
127) received 2 donor lymphocyte infusions (DLIs), but did 
not achieve stable engraftment, and subsequently died due 
to infection and pulmonary hemorrhage.
RC was detected on day 28 after HSCT in 2 patients, 
1 with hemophagocytic lymphohistiocytosis (HLH) and 1 
with SAA. Although the patient with HLH experienced graft 
failure, BM showed autologous recovery, and the patient Korean J Hematol 2011;46:258-64.
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Table 2. Characteristics of patients with high-level mixed chimerism.
UPN Diagnosis 
Age 
(yr)/
sex
Donor 
Conditioning
regimen 
TCD
CD34＋
cells
(×10
6/ 
kg)
Ferritin 
Peak recipient 
chimerism 
(mo)
Graft failure 
(documented 
day)
aGVHD
Salvage 
strategy
Outcome
(follow-up 
months)
72 PRCA 7.2/M MRD CyATG − 40.17 ND 68% (2 mo) No No No CR (＋91)
88 SAA 12.8/F MMUD CyATG − 2 256 96% (3 mo) Yes (61 d) No 2
nd HSCT
a) Death (13)
127 SAA 12.9/M MMRD CyATGTBI ＋ 4.5 5122 66% (2.5 mo) Yes (61 d) No DLI
b) Death (2)
152 KD 4.1/M MRD BuCy − 12.09 31 69% (1 mo) No No No CR (＋53)
All time variables are presented on the basis of the transplantation date.
a)Patient 88 achieved stable engraftment after the second HSCT, but died of transplant-related complications that resulted in multiple organ 
failure 5 months after the second HSCT. 
b)Although patient 127 received a second DLI, he did not achieve engraftment and died of 
transplant-related complications 81 days after HSCT. 
Abbreviations: PRCA, pure red cell anemia; SAA, severe aplastic anemia; KD, Kostmann disease; MRD, matched related donor; MMUD, 
mismatched unrelated donor; MMRD, mismatched related donor; Cy, cyclophosphamide; ATG, antithymocyte globulin; TBI, total body 
irradiation; Bu, busulfan; TCD, T-cell depletion; DLI, donor lymphocyte infusion; CR, complete remission; ND, not done.
Fig. 2. Receiver operating characteristic curve used to determine the 
optimal CD34＋  cell number cut-off value for predicting chimerism.
remained in CR at data cut-off. The SAA patient achieved 
neutrophil engraftment on day 11 (10% autologous portion 
of MC on day 20), but neutropenia occurred at day 14, 
and STR-PCR revealed 100% host signal at day 28. Owing 
to graft failure, the patient underwent a second HSCT and 
achieved CC with stable engraftment.
2. STR-PCR at day 28 post-HSCT
We observed a linear relationship between the degree 
of day-28 STR-PCR and pretransplant ferritin concentra-
tions. Higher ferritin concentrations were significantly asso-
ciated with a higher recipient proportion of MC by day 
28 after HSCT (r
2=0.2,  P=0.03). At day 28 after HSCT, 
STR-PCR values were significantly higher in patients with 
high-level MC than those with transient or low-level MC 
(50.8% vs. 3.7%, P＜0.01).
We observed a linear relationship between the day-28 
STR-PCR and time to engraftment. Specifically, a high pro-
portion of autologous cells at day 28 after HSCT were sig-
nificantly associated with late neutrophil (r
2=0.24, P＜0.01) 
and platelet (r
2=0.15, P=0.02) engraftment. No differences 
were evident in the day-28 STR-PCR between patients with 
PR and CR. However, STR-PCR at day 28 was significantly 
lower in the response than the non-response group (6.1% 
vs. 66.0%, P＜0.01).
3. Variables affecting chimerism
The variables tested for effects on chimerism included 
patient age, disease category, numbers of infused CD34＋ 
and CD3＋ cells, source of stem cells, donor type, degree 
of HLA match, pretransplant serum ferritin concentration, 
and intensity of the conditioning regimen. Increasing MC 
was only observed in patients with BMF. The number of 
infused CD34＋ cells was significantly higher in the CC 
group than in the MC group (13.2×10
6/kg vs. 7.2×10
6/kg, 
respectively; P＜0.01). Similarly, we observed a marked in-
crease in the number of infused CD3＋ cells in the CC 
group compared to the MC group (4.92×10
8/kg vs. 2.61× 
10
8/kg, respectively; P=0.02). The only variable with a sig-
nificant influence on patients’ chimerism status was the num-
ber of infused CD34＋ cells, as determined by multivariate 
analysis. Using ROC curves, the optimal cut-off value of 
CD34＋ cells for predicting the chimerism status was esti-
mated to be 8.35×10
6/kg (70.6% sensitivity, 69.2% specific-
ity), indicating that patients who received less than 8.35× 
10
6/kg of CD34＋ cells are at higher risk of developing MC 
(Fig. 2).
4. Chimerism and transplantation outcomes
The relationship between chimerism status and clinical 
response is shown in Table 3. All patients with CC and 
low-level/transient MC showed clinical responses to HSCT. 
Among the 23 patients with posttransplant CC, 20 achieved 
CR, including 1 who experienced late graft failure 39 months 
after HSCT, but achieved CR after immunosuppressive 
therapy. The remaining 3 patients achieved PR, 1 each with 
adrenoleukodystrophy, Krabbe disease, and SAA. Among the 
23 patients with posttransplant MC, 21 showed clinical re-Korean J Hematol 2011;46:258-64.
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Table 3. Posttransplantation outcome according to chimerism status.
Patients
N=48
CC
N=23
MC
RC
N=2 Transient
N=9
Low-level
N=10
High-level
N=4
CR 39 20 8 8 2 1
P R 6 3120 0
N R 3 0002 1
Graft failure
  Primary
  Late
5
2
3
1
a)
0
1
a)
0
0
0
0
0
0
2
1
1
2
1
1
2
nd T P L 2 0001 1
D L I 1 0001 0
Death 4 1
b) 01
b) 1
b)＋1
c) 0
a)Although the patient maintained CR with CC for 39 months after transplantation, he showed bone marrow hypoplasia in spite of having CC 
and was rescued by immunosuppressive therapy. 
b)Died of transplant-related complications with partial or complete response to the 
transplantation. 
c)Died of graft failure.
Abbreviations: CC, complete donor chimerism; MC, mixed chimerism; RC, recipient chimerism; CR, complete response; PR, partial response;
NR, no response; TPL, transplantation; DLI, donor lymphocyte infusion.
Fig. 3. Kaplan-Meier curves showing overall survival in high-level mixed
chimerism and transient or low-level mixed chimerism groups.
Fig. 4. Kaplan-Meier curves showing event-free survival in high-level 
mixed chimerism and transient or low-level mixed chimerism groups.
sponses to HSCT. Two patients with high-level MC experi-
enced graft failure. The incidence of CR in the transient, 
low-level, and high-level MC subgroups was 89% (8/9), 80% 
(8/10), and 50% (2/4), respectively (P=0.03). The incidence 
of graft failure was significantly higher in the high-level 
MC subgroup than the low-level and transient MC subgroups 
(P=0.03). Higher ferritin concentrations before HSCT (P＜ 
0.01) and lower numbers of infused CD34＋ cells (P=0.01) 
were additionally associated with graft failure.
The incidences of grades II?IV acute and chronic GVHD 
were significantly higher in CC patients than in MC patients 
(56.5% vs. 13.0%, P＜0.01; and 47.8% vs. 21.7%, P=0.04, 
respectively). No significant differences in survival were evi-
dent between the CC and MC groups. However, the OS 
rate was significantly lower in patients with high-level MC 
than in patients with low-level and transient MC (50.0% 
vs. 93.8%, P=0.03; Fig. 3). The EFS rate of patients with 
high-level and low-level/transient MC was 87.5% and 50.0%, 
respectively (P=0.05;  Fig. 4). The causes of death in the 
high-level MC group included graft failure and multi-organ 
failure after second HSCT.
DISCUSSION
This study presents a retrospective analysis of chimerism 
status and the effects of chimerism on clinical outcomes 
in children undergoing HSCT for non-malignant diseases. 
Allo-HSCT was considered the only curative approach for 
non-malignant diseases in our patients. In our cohort of 
48 patients receiving 50 allo-HSCTs, 5 showed graft failure. 
The overall survival rate was 91.5%, similar to that reported 
in earlier studies involving patients with non-malignant dis-
eases [2, 12].
Unlike hematologic malignancies, where 100% donor en-
graftment is always desired, the number of donor cells re-Korean J Hematol 2011;46:258-64.
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quired for sustained engraftment and correction of under-
lying disease in patients with non-malignant disorders may 
be host- and disease-specific. The incidence of MC in our 
study was 48%, similar to that reported previously [13]. 
Possible factors associated with MC development include 
the source of hematopoietic stem cells, intensity of the con-
ditioning regimen, composition of the hematopoietic graft, 
and type of donor [14-16]. In our experiments, the only 
variable that had a significant influence on the achievement 
of MC was the number of infused CD34＋ cells, as determined 
by multivariate analysis. Baron et al. [17] suggested that 
more rapid reconstitution of the T-cell system and reduced 
rejection rates could be achieved by increasing the dose 
of CD34＋ cells administered. Similar findings have been 
reported in other studies [18, 19].
While no significant differences were evident in transplant 
outcomes between patients with MC and those with CC, 
acute and chronic GVHD rates were lower in the MC group. 
Furthermore, all patients with low-level or transient MC 
successfully maintained engraftment and showed clinical re-
sponses to HSCT. The lower incidence of GVHD in the 
MC group may be attributed to a decrease in alloreactive 
T-cells that attack recipient tissues or an imbalance between 
pro-inflammatory and immune-modulating cytokines [20].
STR-PCR at day 28 after allo-HSCT had a predictive value 
for transplantation outcomes. The degree of STR-PCR was 
significantly lower in responders than nonresponders. 
Moreover, day-28 STR-PCR facilitated the identification of 
patients at risk of high-level MC. Therefore, the degree of 
chimerism at day 28 after allo-HSCT may be used as a novel 
platform for additional therapy to induce CR.
H i g h - l e v e l  M C  i s  c o r r e l a t e d  w i t h  a n  i n c r e a s e d  r i s k  o f  
graft failure and rejection [21]. Although we observed no 
significant differences in survival between the CC and MC 
groups, we found that patients with high-level MC displayed 
a higher rate of graft failure and lower survival than those 
with low-level or transient MC. MC is not necessarily asso-
ciated with graft rejection, but patients with more than 30% 
recipient cells in serial samples may be at a higher risk 
of graft failure. However, no graft loss was observed in 50% 
of patients with increasing MC. Thus, the risk of graft re-
jection after allo-HSCT may be limited to the period before 
the development of tolerance, suggesting that chimerism 
testing is not predictive of rejection once tolerance to donor 
cells has been established. Our understanding of tolerance 
development following allo-HSCT for non-malignant dis-
eases is still incomplete.
In patients undergoing allo-HSCT with either myeloa-
blative conditioning or reduced intensity conditioning for 
hematologic malignancies, elevated pretransplant serum fer-
ritin concentration, a surrogate marker of iron overload, 
has been associated with lower OS and increased nonrelapse 
mortality [22-24]. We observed an association of pretrans-
plant ferritin concentration with day-28 STR-PCR, but not 
chimerism status thereafter, during the first year after HSCT. 
Patients experiencing graft failure displayed extremely high 
ferritin concentrations. Iron overload is known to be asso-
ciated with free radical generation and tissue damage [23]. 
Overloaded iron may have accumulated in the BM, resulting 
in deterioration of microenvironmental functions. However, 
the number of patients with graft failure was relatively small, 
suggesting the need for larger-scale studies.
Our study had some limitations. First, the retrospective 
study design, small sample size, and heterogeneous diseases, 
and transplantation procedures may have precluded mean-
ingful analyses. Nevertheless, this was a relatively large-scale 
investigation of this rare disease state in children, managed 
uniformly in a single center. Next, we did not evaluate line-
age-specific chimerism in individual patients. Finally, since 
treatment was based on individual clinical situations, we 
did not analyze what interventions may have been prompted 
by the results of chimerism assays, thus affecting patients’ 
clinical outcomes.
In summary, our findings suggest that posttransplant MC 
in non-malignant diseases indicates a tolerant state associated 
with decreased incidence of acute and chronic GVHD. MC 
may thus be sufficient to cure non-malignant disease. 
However, patients subsequently presenting with more than 
30% recipient cells in serial samples may be at a higher 
risk of graft failure. The degree of chimerism at day 28 
after HSCT may allow the prediction of subsequent clinical 
responses to HSCT. Our findings collectively highlight the 
potential value of serial chimerism assays combined with 
clinical evaluation in providing information on trans-
plantation outcomes.
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